Company: PSTV
Filing Date: 2025-04-11
Form Type: POS AM
Source: 0001193125-25-079109
Chunk: 9

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-11
Form: POS AM
Chunk 9
---
 test, to be re-introduced to the U.S. market starting in the second quarter of 2025 after we complete a number of steps related to
certifications, state licensure, payor coverages, reimbursement codes and financing.

Company Information

In March 2025, we moved our headquarters to Houston, Texas, in proximity to world-class cancer institutions and researchers. Our principal executive offices
are located at 2710 Reed Road, Suite 160, Houston, Texas 77051, and our telephone number is (737) 255-7194. We maintain a website at www.plustherapeutics.com. We make available free of charge through
our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and amendments to these reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), as soon as reasonably practicable after we electronically file such material with, or furnish such material to, the SEC. These reports and other information are also available, free of charge, at www.sec.gov.
Information contained on, or that can be accessed through, the websites referenced in this prospectus are not a part of, or incorporated by reference into, this prospectus.

1

The Offering

| Issuer | Plus Therapeutics, Inc. |

| Common stock offered by the selling stockholders | Up to 3,248,878 shares of common stock, consisting of (i) 108,685 shares of common stock, (ii) 48,285 shares of common stock issuable upon exercise of Series A Warrants, and (iii) 3,091,908 shares of common stock issuable upon exercise of Series 
 B Warrants that we issued in a private placement transaction that closed on May 9, 2024 (the “May 2024 PIPE Financing”).                                                                                                                              |

| Use of proceeds | We will not receive any proceeds from the sale of the shares of common stock covered by this prospectus. We may, however, receive proceeds from the exercise of the Warrants if such Warrants are exercised for cash. The exercise price of each          
 Series A Warrant and Series B Warrant from the Initial Subscription is $1.772 per share, and $1.908 per share in the Additional Subscription, except that the exercise price for the Series A Warrants and Series B Warrants held by the